Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ADH5 | P11766 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28179724 | 0.98 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP3A4MAPTADH5LOXL2 | |
| SCHEMBL6361094 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL28185877 | 0.72 | — | — | |
| SCHEMBL28581728 | 0.72 | MAPT (0.61) | SMN1; SMN2CYP3A4MAPTLOXL2LMNA | |
| SCHEMBL31241182 | 0.72 | MAPT (0.61) | SMN1; SMN2CYP3A4MAPTLOXL2LMNA | |
| SCHEMBL5797000 | 0.68 | CYP3A4 (0.44) | SMN1; SMN2CYP3A4MAPTADH5LOXL2 | |
| SCHEMBL2694847 | 0.68 | LOXL2 (0.41) | SMN1; SMN2CYP3A4MAPTLOXL2LMNA | |
| SCHEMBL30837557 | 0.68 | CYP3A4 (0.41) | CYP3A4ADH5CYP2A6MEN1KMT2A | |
| SCHEMBL28175006 | 0.68 | CYP3A4 (0.60) | SMN1; SMN2CYP3A4MAPTADH5LMNA | |
| SCHEMBL17610176 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240067779-A1 | METALLOPOLYMERS AND ICLICK SYNTHESIS THEREOF | UNIVERSITY OF TEXAS SAN ANTONIO (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4305032-A1 | 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| EP-4305031-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| US-11814462-B2 | Functionalized cyclic polymers and methods of preparing same | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230303600-A1 | TETHERED ALKYLIDENE AND METHODS OF MAKING THE SAME | NATIONAL SCIENCE FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023136924-A1 | TETHERED ALKYLIDENES FROM ORGANOAZIDES FOR CYCLIC POLYMER SYNTHESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-03-02 | — | — | US | disclosed |
| CN-115361870-A | Agrochemical composition | UPL有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-109843332-A | Zwitterionic microgels, components thereof and related formulations and methods of use thereof | 华盛顿大学 | 2019-06-04 | — | — | CN | disclosed |
| CN-108025286-A | The composition and method comprising metal organic framework for selective olefin oligomerisation | 麻省理工学院 | 2018-05-11 | — | — | CN | disclosed |
| CN-105992763-A | Neprilysin inhibitors | 施万生物制药研发IP有限责任公司 | 2016-10-05 | — | — | CN | disclosed |
| CN-105839151-A | Even-plating agent of copper electroplating bath of HDI board used for copper interconnection and copper electroplating bath | 电子科技大学 | 2016-08-10 | — | — | CN | disclosed |
| CN-101912381-B | For treating the method and composition of ectoparasitic infection | 皮埃蒙特医药品有限公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-103249728-B | Novel triazole compounds III | HOFFMANN LA ROCHE | 2015-01-21 | — | — | CN | disclosed |
| CN-103249728-A | Novel triazole compounds III | HOFFMANN LA ROCHE | 2013-08-14 | — | — | CN | disclosed |
| CN-1655673-B | Methods and compositions for treating ectoparasite infections | PIEDMONT PHARMACEUTICALS LLC | 2013-05-22 | — | — | CN | disclosed |
| CN-101912381-A | Methods and compositions for treating ectoparasite infestation | PIEDMONT PHARMACEUTICALS LLC | 2010-12-15 | — | — | CN | disclosed |
| CN-1655673-A | Methods and compositions for treating ectoparasite infections | PIEDMONT PHARMACEUTICALS LLC (US) | 2005-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | SMN1; SMN2 1965/4885CYP3A4 3272/4885MAPT 4288/4885 |
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | DCK, POLK, ERCC2 | SMN1; SMN2 3212/4885CYP3A4 2477/4885MAPT 3302/4885 |
| US-20230303600-A1 | TETHERED ALKYLIDENE AND METHODS OF MAKING THE SAME | CYCS, DNMT1, CCNY | SMN1; SMN2 1421/4885CYP3A4 1115/4885MAPT 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.